Rare neurological condition is 'important potential risk' of Pfizer's RSV vaccine, FDA says

Two people who received Pfizer's respiratory syncytial virus (RSV) vaccine during a clinical trial were later diagnosed with Guillain-Barre syndrome, and the US Food and Drug Administration has asked Pfizer to conduct a safety study if the shot is approved, according to agency documents released Friday.

from CNN.com - RSS Channel - HP Hero https://ift.tt/TP618BC
via IFTTT